DPP4 and neoplasm: CD26 3G CAR-T-cells demonstrated greater anti-tumor activity than CD26 2G CAR-T-cells at both 1: 1 and 5: 1 effector: target cells ratios (p < 0.001 and 0.004, respectively) (Figure 4A).